Kira Weber, APRN
Acute Care · Lafayette, LANPI 1093175895
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 32.3% of the total. Among acute care clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- AbbVie$962
- Biohaven Pharmaceuticals, Inc.$557
- Argenx US, Inc.$321
- Jazz Pharmaceuticals Inc.$264
- Amgen$192
- plus $870 from 10 others
What the payments were for
- Food & beverage$4,60198%
- Education$772%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 115 | $1,513 |
| AbbVie(2 entities) | 63 | $962 |
| Biohaven Pharmaceuticals, Inc. | 33 | $557 |
| Argenx US, Inc. | 9 | $321 |
| Jazz Pharmaceuticals Inc. | 10 | $264 |
| Amgen(2 entities) | 12 | $192 |
| Acadia Pharmaceuticals Inc | 7 | $183 |
| UCB, Inc. | 11 | $178 |
| Avanir Pharmaceuticals, Inc. | 1 | $122 |
| AstraZeneca | 1 | $115 |
| Pfizer | 5 | $93 |
| Averitas Pharma Inc. | 3 | $79 |
| Insightec,inc | 2 | $34 |
| Piramal Critical Care | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$123
- XYWAV$123
- NUEDEXTA$122
- Fintepla$115
- NURTEC ODT$112
How this compares
$4,678 in reported general payments places this provider in the 90th percentile of 248 acute care providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 22 | $72,502 |
| Nurtec OdtRimegepant Sulfate | 41 | $69,908 |
| QuliptaAtogepant | 39 | $45,613 |
| TopamaxTopiramate | 27 | $33,211 |
| UbrelvyUbrogepant | 24 | $28,951 |
| Emgality PenGalcanezumab-Gnlm | 36 | $23,873 |
| Aimovig AutoinjectorErenumab-Aooe | 21 | $21,178 |
| RytaryCarbidopa/Levodopa | 34 | $11,299 |
| Lacosamide | 115 | $9,094 |
| Levetiracetam | 274 | $8,775 |
| OngentysOpicapone | 12 | $8,233 |
| TrintellixVortioxetine Hydrobromide | 11 | $6,244 |
| Carbamazepine ErCarbamazepine | 25 | $5,563 |
| Aripiprazole | 19 | $4,830 |
| Memantine Hcl | 197 | $4,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $962 | $74,56463 claims |
| PfizerNurtec Odt, Dilantin | $93 | $72,57066 claims |
| Acadia Pharmaceuticals IncNuplazid | $183 | $72,50222 claims |
| Neurocrine Biosciences, Inc.Ongentys | $1,513 | $8,23312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 248 acute care providers in Louisiana.
Other acute care in Lafayette
- Precious HodgesLafayette$70K
- Jeremy TerroLafayette$11K
- Kristen LasseigneLafayette$3K
- Stepheny SumrallLafayette$2K
- Brinton FegleyShreveport$61K
- Charles JarreauNew Orleans$40K
- Jeremy DavisShreveport$35K
- Heather MecomShreveport$17K
- Mary HireShreveport$11K
- Jacquelyn CosterHouma$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.